Sueoka-Aragane et al. observed that the analysis of ctDNA by NGS could be a promising tool for the evaluation of the efficacy of osimertinib in NSCLC with EGFR T790M mutation [68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.